Group 1 - The stock price of Beijing Baipusi Biotechnology Co., Ltd. dropped by 5.15% to 57.67 CNY per share, with a total market capitalization of 9.68 billion CNY as of the report date [1] - The company was established on July 22, 2010, and went public on October 18, 2021, focusing on providing key biological reagent products and technical services, with main revenue sources being recombinant proteins (82.27%), antibodies and other reagents (12.88%), technical services (3.04%), and others (1.80%) [1] Group 2 - The fund "Lubo Mai China Medical Health Stock Initiation A" holds 15,700 shares of Baipusi, accounting for 3.84% of the fund's net value, making it the ninth largest holding [2] - The fund was established on December 26, 2023, with a current scale of 14.52 million CNY, achieving a year-to-date return of 44.16% and a one-year return of 58.26% [2] Group 3 - The fund manager of "Lubo Mai China Medical Health Stock Initiation A" is Li Tao, who has been in the position for 1 year and 261 days, with total assets under management of 29.25 million CNY [3] - During Li Tao's tenure, the best fund return was 17%, while the worst was 15.79% [3]
百普赛斯股价跌5.15%，中国路博迈基金旗下1只基金重仓，持有1.57万股浮亏损失4.91万元